Replimune

Replimune is developing novel, proprietary oncolytic immunotherapies intended to improve both the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released.
Type
Private
HQ
Milton, GB
Founded
2015
Replimune was founded in 2015 and is headquartered in Milton, GB

Replimune Office Locations

Replimune has offices in Milton and Woburn
Milton, GB (HQ)
69 Park Dr
Woburn, US
18 Commerce Way

Replimune Data and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$30 m

Latest funding size

$30 m

Time since last funding

almost 2 years

Investors

Replimune's latest funding round in September 2015 was reported to be $30 m. In total, Replimune has raised $30 m

Replimune Financial Metrics

GBP

Net income (FY, 2016)

(478.4 k)

Cash (31-Mar-2016)

9.7 m
GBPFY, 2016

Pre tax profit

(679.4 k)

Net Income

(478.4 k)
GBPFY, 2016

Cash

9.7 m

Current Assets

10.6 m

PP&E

115.6 k

Total Assets

10.8 m
GBPFY, 2016

Cash From Operating Activities

(1.4 m)

Cash From Financing Activities

11 m

Income Taxes Paid

201 k
Y, 2016

Financial Leverage

1 x
Show all financial metrics

Traffic Overview of Replimune

Replimune Company Life and Culture

You may also be interested in